Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial
about
High-grade glioma management and response assessment-recent advances and current challengesQuantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR ImagesMultimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR ImagingMR Imaging Biomarkers in Oncology Clinical TrialsPhysiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.An Update on the Approach to the Imaging of Brain Tumors.Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange.Textural features of dynamic contrast-enhanced MRI derived model-free and model-based parameter maps in glioma grading.A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials.DCE-MRI prediction of survival time for patients with glioblastoma multiforme: using an adaptive neuro-fuzzy-based model and nested model selection technique.Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.Evidence for rCBV as an early response marker following bevacizumab treatment.Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.The siren song of bevacizumab: swan song or clarion call?Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma.Conventional and advanced magnetic resonance imaging in patients with high grade glioma.Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges.Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study.Imaging in neuro-oncology.Evaluation of recurrent high-grade gliomas treated with bevacizumab: A preliminary report of 3D pseudocontinuous artery spin labeling.Clinical Validation of Automatable Gaussian Normalized CBV in Brain Tumor Analysis: Superior Reproducibility and Slightly Better Association with Survival than Current Standard Manual Normal Appearing White Matter NormalizationImaging biomarkers guided anti-angiogenic therapy for malignant gliomas
P2860
Q26740664-20B91284-4E08-4586-99B4-701652190EC2Q26743358-66DFE679-1989-4D7E-A0BD-4D3B2DBC1C82Q26796223-05BB0628-C9CD-499E-A080-2B70E50E1A57Q30364608-97E74BDE-0051-49D1-86E3-39500F4C62C4Q35771783-9C27BB26-56B7-4A39-B098-47ADDB5FBEB9Q36275542-CC0A0239-7F0B-4CEF-A60B-D8A2E2DBD608Q36374577-D1BD18B0-AD0D-45F0-A495-79A3A381A1DFQ36378153-A3B0C03C-9C7A-4903-9620-CDB326E6936EQ36785131-EC5E411B-B53E-43CF-A731-B4BEDF9F9A8AQ37172332-F20959E9-43A8-46F8-B751-E1555B12ABBDQ38606106-66F6FBC5-0B8C-46E5-AC0E-6AF4FD13D656Q38741691-73DBB989-5533-482B-84BB-9156F12DB34DQ38764240-BAD00AB9-0E95-4DCD-B8DB-7546201FABC1Q38815926-8159DD19-CA52-4DE7-B960-E23236A2881FQ38975001-8C4E01AD-626B-4EA9-9A19-D34E753E3EF5Q39761792-F6CED63D-FA8E-4B30-9A2F-82232164A5D5Q43170408-5C8D0711-5B54-4399-8F41-266D756598DDQ43170414-DEB27F3B-BF8B-4382-9384-FD19A4EA6500Q48220641-24CEB5A0-72B7-4BA0-8007-700A3AD291DBQ49818975-B9A9A943-0A38-4447-A370-0605261961C7Q50578662-29C9FA68-A69F-4157-8830-27E50C6103C2Q52562075-A4C7A76C-E26C-4037-B966-21B1C068B6FCQ52904949-088340E9-E13D-4F58-9081-5096E8317567Q52950126-94FA94AE-268C-49CD-A6AC-B502AEF3CF45Q54973707-E191B73C-9C2B-447A-ABE6-B298866CF93BQ55458839-D69BF42E-8043-4E84-BF5C-E4CB8E446BAEQ56761469-DE30DB3F-88D4-496D-A1DF-741DC1886A01Q57177114-C0669CCD-0E10-47E9-AB9C-2DA2003B51CD
P2860
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dynamic susceptibility contras ...... 77/RTOG 0625 multicenter trial
@ast
Dynamic susceptibility contras ...... 77/RTOG 0625 multicenter trial
@en
type
label
Dynamic susceptibility contras ...... 77/RTOG 0625 multicenter trial
@ast
Dynamic susceptibility contras ...... 77/RTOG 0625 multicenter trial
@en
prefLabel
Dynamic susceptibility contras ...... 77/RTOG 0625 multicenter trial
@ast
Dynamic susceptibility contras ...... 77/RTOG 0625 multicenter trial
@en
P2093
P2860
P356
P1433
P1476
Dynamic susceptibility contras ...... 77/RTOG 0625 multicenter trial
@en
P2093
A Gregory Sorensen
Jerrold L Boxerman
Kathleen M Schmainda
Mark R Gilbert
Melissa Prah
Zheng Zhang
P2860
P304
P356
10.1093/NEUONC/NOU364
P577
2015-02-02T00:00:00Z